<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00717249</url>
  </required_header>
  <id_info>
    <org_study_id>CR-1513</org_study_id>
    <nct_id>NCT00717249</nct_id>
  </id_info>
  <brief_title>Vistakon Investigational Contact Lenses Worn for Daily Wear</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the performance of an investigational contact lens to a currently
      marketed lens.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Slit Lamp Findings</measure>
    <time_frame>6 months</time_frame>
    <description>Each subjects' eye was examined using a bio-microscope. Slit lamp findings were graded using a 5- point scale. (Grade 0, 1, 2, 3 and 4). The data was dichotomized by creating 2 groups. Eyes with Grade 3 or Grade 4; eyes with Grade 2 or lower. The number of eyes with Grade 3 or Grade 4 was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject Reported Symptoms</measure>
    <time_frame>6 months</time_frame>
    <description>Subjects were asked &quot;Have you experienced any symptoms or problems since your last visit?&quot; at each visit and responded 'yes' or 'no' for each eye; at each visit(baseline, 2-, 4-, 12- and 26- week follow-up evaluations). If a subject responded 'yes' then the symptoms was classified into one of the four categories, &quot;Dryness&quot;, &quot;Other&quot;, &quot;Cloudy/ Blurry / Hazy&quot;, &quot;Irritation / Discomfort&quot;. The percentage of each response across all visits was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Binocular LogMAR Visual Acuity was taken under low luminance and high contrast conditions using ETDRS acuity charts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Contact Lens Wear Time</measure>
    <time_frame>6 Months</time_frame>
    <description>The Contact lens wear time for the study contact lenses was collected for each subject. The average wear time for each contact lens was reported.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">529</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Test Lens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>galyfilcon A contact lens with a silver additive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Lens</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>galyfilcon A control contact lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>galyifilcon A control lens</intervention_name>
    <description>Marketed daily wear contact lens</description>
    <arm_group_label>Control Lens</arm_group_label>
    <other_name>ACUVUE Advance with Hydraclear</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>galyfilcon A with a silver additive</intervention_name>
    <description>Investigational daily wear contact lens</description>
    <arm_group_label>Test Lens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject must be at least 18 years of age.

          2. Both males and females may be enrolled.

          3. The subject must read, understand, and sign for themselves the STATEMENT OF INFORMED
             CONSENT and be provided with a copy of the form.

          4. The subject is able and willing to wear soft contact lenses on a daily basis for a six
             month duration.

        Exclusion Criteria:

          1. The subject must be free of Grade 2 or greater slit lamp findings (edema, corneal
             neovascularization, corneal staining, tarsal abnormalities, conjunctival injection,
             and other ocular abnormality), which would contraindicate contact lens wear.

          2. Any active ocular (i.e. corneal infiltrates, conjunctiva, lids, and intraocular)
             infection or inflammation of an allergic, bacterial, or viral etiology.

          3. Entropion, ectropion, chalazia, recurrent styes, glaucoma or glaucoma suspect, history
             of recurrent corneal erosions and aphakia.

          4. The following medications are prohibited (at lease one week prior to enrollment): oral
             retinoid isoretinoin (e.g. Accutane), oral tetracyclines, topical scopolamine, oral
             (e.g. antihistamines (e.g. Seldane, Chlor-Trimeton, and Benadryl), and ophthalmic
             antihistamic Beta-adrenergic blockers (e.g. Propranolol, Timolol, and Practolol),
             systemic steroids, and and prescribed or OTC ocular medication. Any prescription or
             PTC medications or preparations containing silver.

          5. Moderate or above corneal distortion by keratometry.

          6. Known allergy to silver, silver ions, or silver containing compounds.

          7. Abnormal discoloration of the cornea and/or conjunctiva.

          8. Routine exposure to silver, silver ions, or silver containing compounds.

          9. The subject must be free of systemic diseases which may interfere with contact lens
             wear: diabetes, hyperthyroidism, recurrent herpes simplex/zoster, Sjogren's syndrome,
             xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases
             (e.g. AIDS)

         10. Free of systemic and infectious diseases: hepatitis and tuberculosis.

         11. Subjects must be HIV negative.

         12. The subject must not be currently be pregnant or lactating (Subject becoming pregnant
             during the study will be discontinued).

         13. The subject's eyes must be best corrected to a visual acuity of 20/30 or better in
             each eye.

         14. The subject must not have more than 1.00D of refractive astigmatism in either eye.

         15. The subject's distance spherical contact lens prescription must be between -1.00D and
             -6.00D.

         16. The subject must not be monovision corrected.

         17. The subject must have no history of solution reaction to Opti-free RepleniSH MPDS-No
             Rub Solution.

         18. The subject must not have any previous history or signs of a contact lens related
             corneal inflammatory event (i.e. past peripheral ulcers or round peripheral scars)

         19. The subject must not have participated in a device or pharmaceutical clinical trial
             within 30 days prior to study enrollment.

         20. The subject must not have had an eye injury within 8 weeks prior to study enrollment.

         21. The subject must not have had previous eye surgery.

         22. The subject must be successfully trial fitted with the study contact lenses.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cole, Cole, and Krohn</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. James R. Dugue Family Optometrist</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukai and Associates</name>
      <address>
        <city>Louisville</city>
        <state>Colorado</state>
        <zip>80027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baymeadows Vision Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eyecare Associates</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advantage Eyecare Associates, LLC</name>
      <address>
        <city>Neodesha</city>
        <state>Kansas</state>
        <zip>66757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InSight Eyecare</name>
      <address>
        <city>Warrensburg</city>
        <state>Missouri</state>
        <zip>64093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Eyecare</name>
      <address>
        <city>Jamestown</city>
        <state>New York</state>
        <zip>14750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drs. Quinn, Quinn and Associates</name>
      <address>
        <city>Athens</city>
        <state>Ohio</state>
        <zip>45701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Michael H. Greenburg, Inc.</name>
      <address>
        <city>Chagrin Falls</city>
        <state>Ohio</state>
        <zip>44023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Ohio Eyecare</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James W. Kershaw OD, Inc.</name>
      <address>
        <city>North Olmsted</city>
        <state>Ohio</state>
        <zip>44070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Hills Vision Center</name>
      <address>
        <city>Moon Township</city>
        <state>Pennsylvania</state>
        <zip>15108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nittany Eye Associates</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. David W. Ferris and Associates</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Vision</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William J. Bogus OD</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Speciliasts, Ltd</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Snowy Range Vision Center</name>
      <address>
        <city>Laramie</city>
        <state>Wyoming</state>
        <zip>82070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2008</study_first_submitted>
  <study_first_submitted_qc>July 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2008</study_first_posted>
  <results_first_submitted>April 20, 2016</results_first_submitted>
  <results_first_submitted_qc>April 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 26, 2016</results_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 529 subjects were enrolled in this study. Of those enrolled subjects, 33 did not meet the eligibility criteria and 496 were randomized to either the test or control lens using a 2:1 allocation. Of those randomized subjects 491 were successfully dispensed. Of the dispensed subjects 454 subjects completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Galyfilcon A w/ Silver</title>
          <description>Subjects that were randomized to receive the galyfilcon A contact lens with a silver additive during the entire course of the study.</description>
        </group>
        <group group_id="P2">
          <title>Galyfilcon A</title>
          <description>Subjects that were randomized to receive the galyfilcon A contact lens with a silver additive during the entire course of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="326"/>
                <participants group_id="P2" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="304"/>
                <participants group_id="P2" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lens Discomfort</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory visual Response</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject became Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory Physiological Response</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Gastric Surgery</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Diagnosed with Diabetes</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Diagnosed with Multiple Scletosis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject relocated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Headaches</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects that were dispensed a study lens.</population>
      <group_list>
        <group group_id="B1">
          <title>Galyfilcon A w/ Silver</title>
          <description>Subjects that were randomized to receive the galyfilcon A contact lens with a silver additive during the entire course of the study.</description>
        </group>
        <group group_id="B2">
          <title>Galyfilcon A</title>
          <description>Subjects that were randomized to receive the galyfilcon A contact lens during the entire course of the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="326"/>
            <count group_id="B2" value="165"/>
            <count group_id="B3" value="491"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.9" lower_limit="18" upper_limit="60"/>
                    <measurement group_id="B2" value="29.8" lower_limit="18" upper_limit="51"/>
                    <measurement group_id="B3" value="30.9" lower_limit="18" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="326"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Slit Lamp Findings</title>
        <description>Each subjects' eye was examined using a bio-microscope. Slit lamp findings were graded using a 5- point scale. (Grade 0, 1, 2, 3 and 4). The data was dichotomized by creating 2 groups. Eyes with Grade 3 or Grade 4; eyes with Grade 2 or lower. The number of eyes with Grade 3 or Grade 4 was reported.</description>
        <time_frame>6 months</time_frame>
        <population>The analysis population consists of subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Galyfilcon A w/ Silver</title>
            <description>Subjects that were randomized to receive the galyfilcon A contact lens with a silver additive during the entire course of the study.</description>
          </group>
          <group group_id="O2">
            <title>Galyfilcon A</title>
            <description>Subjects that were randomized to receive the galyfilcon A contact lens during the entire course of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Slit Lamp Findings</title>
          <description>Each subjects' eye was examined using a bio-microscope. Slit lamp findings were graded using a 5- point scale. (Grade 0, 1, 2, 3 and 4). The data was dichotomized by creating 2 groups. Eyes with Grade 3 or Grade 4; eyes with Grade 2 or lower. The number of eyes with Grade 3 or Grade 4 was reported.</description>
          <population>The analysis population consists of subjects that completed all study visits without a major protocol deviation.</population>
          <units>Number of Subject Eyes</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Subject Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="608"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subject Reported Symptoms</title>
        <description>Subjects were asked &quot;Have you experienced any symptoms or problems since your last visit?&quot; at each visit and responded 'yes' or 'no' for each eye; at each visit(baseline, 2-, 4-, 12- and 26- week follow-up evaluations). If a subject responded 'yes' then the symptoms was classified into one of the four categories, &quot;Dryness&quot;, &quot;Other&quot;, &quot;Cloudy/ Blurry / Hazy&quot;, &quot;Irritation / Discomfort&quot;. The percentage of each response across all visits was reported.</description>
        <time_frame>6 months</time_frame>
        <population>The analysis population consists of subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Galyfilcon A w/ Silver</title>
            <description>Subjects that were randomized to receive the galyfilcon A contact lens with a silver additive during the entire course of the study.</description>
          </group>
          <group group_id="O2">
            <title>Galyfilcon A</title>
            <description>Subjects that were randomized to receive the galyfilcon A contact lens during the entire course of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Reported Symptoms</title>
          <description>Subjects were asked &quot;Have you experienced any symptoms or problems since your last visit?&quot; at each visit and responded 'yes' or 'no' for each eye; at each visit(baseline, 2-, 4-, 12- and 26- week follow-up evaluations). If a subject responded 'yes' then the symptoms was classified into one of the four categories, &quot;Dryness&quot;, &quot;Other&quot;, &quot;Cloudy/ Blurry / Hazy&quot;, &quot;Irritation / Discomfort&quot;. The percentage of each response across all visits was reported.</description>
          <population>The analysis population consists of subjects that completed all study visits without a major protocol deviation.</population>
          <units>Percentage of Observations</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of Observations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2548"/>
                <count group_id="O2" value="1260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dryness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9"/>
                    <measurement group_id="O2" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cloudy/ Blurry / Hazy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritation / Discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity</title>
        <description>Binocular LogMAR Visual Acuity was taken under low luminance and high contrast conditions using ETDRS acuity charts.</description>
        <time_frame>6 months</time_frame>
        <population>The analysis population consists of subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Galyfilcon A w/ Silver</title>
            <description>Subjects that were randomized to receive the galyfilcon A contact lens with a silver additive during the entire course of the study.</description>
          </group>
          <group group_id="O2">
            <title>Galyfilcon A</title>
            <description>Subjects that were randomized to receive the galyfilcon A contact lens during the entire course of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity</title>
          <description>Binocular LogMAR Visual Acuity was taken under low luminance and high contrast conditions using ETDRS acuity charts.</description>
          <population>The analysis population consists of subjects that completed all study visits without a major protocol deviation.</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.0891"/>
                    <measurement group_id="O2" value="-0.009" spread="0.0866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Contact Lens Wear Time</title>
        <description>The Contact lens wear time for the study contact lenses was collected for each subject. The average wear time for each contact lens was reported.</description>
        <time_frame>6 Months</time_frame>
        <population>The analysis population consists of subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Galyfilcon A w/ Silver</title>
            <description>Subjects that were randomized to receive the galyfilcon A contact lens with a silver additive during the entire course of the study.</description>
          </group>
          <group group_id="O2">
            <title>Galyfilcon A</title>
            <description>Subjects that were randomized to receive the galyfilcon A contact lens during the entire course of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Contact Lens Wear Time</title>
          <description>The Contact lens wear time for the study contact lenses was collected for each subject. The average wear time for each contact lens was reported.</description>
          <population>The analysis population consists of subjects that completed all study visits without a major protocol deviation.</population>
          <units>time in hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="13.92" upper_limit="14.03"/>
                    <measurement group_id="O2" value="14.0" lower_limit="13.95" upper_limit="14.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the duration of the study. Approximately 6 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Galyfilcon A w/ Silver</title>
          <description>Subjects that were randomized to receive the galyfilcon A contact lens with a silver additive during the entire course of the study.</description>
        </group>
        <group group_id="E2">
          <title>Galyfilcon A</title>
          <description>Subjects that were randomized to receive the galyfilcon A contact lens during the entire course of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Iritis</sub_title>
                <description>Note from Dr. Not Lens Related. Possible Cause: “Iritis secondary to cornea culture”</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brian Pall, O.D., M.S. Principal Research Optometrist</name_or_title>
      <organization>Johnson &amp; Johnson Vision Care Inc.</organization>
      <phone>904-443-3500 ext 1290</phone>
      <email>BPALL@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

